Patents Assigned to Lupin Limited
  • Process for preparing pharmaceutical ophthalmic compositions
    Patent number: 8614210
    Abstract: Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry comprising a carbonic anhydrase inhibitor and a surfactant; b) preparing a polymer slurry comprising a polymer and water; c) preparing a solution comprising tonicity and preservative agents; d) mixing the polymer slurry of step b and the solution of step c, to form a vehicle concentrate and adjusting pH; e) adding the slurry of step a, to the vehicle concentrate of step d and mixing to homogenize; f) autoclaving the mixture of step e; g) sizing the mixture of step f, under aseptic condition.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: December 24, 2013
    Assignee: Lupin Limited
    Inventors: Pravin Meghrajji Bhutada, Ashish Ashokrao Deshmukh, Sajeev Chandran, Shirishkumar Kulkarni
  • HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS
    Publication number: 20130331387
    Abstract: Disclosed is a compound of formula (I), wherein Z, m and R1-R6 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.
    Type: Application
    Filed: February 22, 2012
    Publication date: December 12, 2013
    Applicant: Lupin Limited
    Inventors: Neelima Sinha, Gourhari Jana, Sachchidanand Sachchidanand, Sanjay Pralhad Kurhade, Navnath Popat Karche, Anil Kashiram Hajare, Ajay Ramchandra Tilekar, Venkata P. Palle, Rajender Kumar Kamboj
  • PROCESS FOR PREPARATION OF LEVONORGESTREL
    Publication number: 20130324748
    Abstract: The present invention provides an improved process for preparation of levonorgestrel (3) which comprises of hydrolysis of 13?-ethyl-3-methoxy-17?-ethynyl-gona-2,5(10)-dien-17?-ol (2) with an acid in aprotic solvent. The present invention also provides a novel process for purification of crude levonorgestrel (3) by recrystallization from N,N-dimethyl formamide-water; methanol-water mixture.
    Type: Application
    Filed: February 14, 2012
    Publication date: December 5, 2013
    Applicant: LUPIN LIMITED
    Inventors: Swapnil Ajit Zadbuke, Kishor Gulabrao Mehare, Himanshu Madhav Godbole, Girij Pal Singh
  • Sustained Release Composition of Memantine
    Publication number: 20130323309
    Abstract: A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3:5:1, optionally containing an immediate release coating having memantine where the immediate release coating is applied over the sustained release coating.
    Type: Application
    Filed: February 7, 2012
    Publication date: December 5, 2013
    Applicant: LUPIN LIMITED
    Inventors: Pravin Meghrajji Bhutada, Ashish Ashokrao Deshmukh, Sajeev Chandran, Vineeth Raghavan, Shirishkumar Kulkarni
  • ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE
    Publication number: 20130317063
    Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.
    Type: Application
    Filed: February 3, 2012
    Publication date: November 28, 2013
    Applicant: LUPIN LIMITED
    Inventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
  • PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR
    Publication number: 20130310419
    Abstract: The present invention is related to pyrrole derivatives of formula I as the modulators of nicotinic acetylcholine receptors particularly the ?7 subtype. The invention includes pyrrole derivatives, analogues, their prodrugs, their isotopes, their metabolites, pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them. Owing to the modulatory activity of the pyrrole derivatives on the nicotinic acetylcholine receptors, the invention finds application in the prophylaxis and therapy of disorders encompassing the involvement of cholinergic transmission in the central and peripheral nervous system.
    Type: Application
    Filed: January 31, 2012
    Publication date: November 21, 2013
    Applicant: LUPIN LIMITED
    Inventors: Neelima Sinha, Gourhari Jana, Navnath Popat Karche, Shridhar Keshav Adurkar, Girish Dhanraj Hatnapure, Venkata P. Palle, Rajender Kumar Kamboj
  • STEREOSELECTIVE PROCESS FOR PREPARATION OF 1,3-OXATHIOLANE NUCLEOSIDES
    Publication number: 20130296562
    Abstract: The present invention relates to a stereoselective glycosylation for the preparation of 1,3-oxathiolane nucleoside in high yield and high optical purity. The invention specifically relates to a process of the preparation of Lamivudine and Emtricitabine using zirconium (IV) chloride (ZrCl4) as a catalyst in glycosylation.
    Type: Application
    Filed: January 10, 2012
    Publication date: November 7, 2013
    Applicant: LUPIN LIMITED
    Inventors: Bhairab Nath Roy, Girij Pal Singh, Dhananjai Srivastava, Umesh Parasharam Aher, Sudhakar Uttam Patil
  • BICYCLIC GPR119 MODULATORS
    Publication number: 20130245000
    Abstract: The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I).
    Type: Application
    Filed: November 24, 2011
    Publication date: September 19, 2013
    Applicant: LUPIN LIMITED
    Inventors: Rajesh Thotapally, Onkar Gangaram Kachi, Atish Harishchandra Rodge, Ashok Bhau Pathak, Bhavana Shrirang Kardile, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
  • OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS
    Publication number: 20130225600
    Abstract: The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).
    Type: Application
    Filed: October 31, 2011
    Publication date: August 29, 2013
    Applicant: LUPIN LIMITED
    Inventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • PROCESS FOR PREPARATION OF ESTRADIOL VALERATE AND A NOVEL CRYSTALLINE FORM A OF ESTRADIOL DIVALERATE
    Publication number: 20130225845
    Abstract: The present invention relates to the process for the preparation of estradiol valerate (I) which involves isolation of crystalline estradiol divalerate (III) by crystallization from an alcoholic solvent.
    Type: Application
    Filed: October 28, 2011
    Publication date: August 29, 2013
    Applicant: LUPIN LIMITED
    Inventors: Sachin Arun Sasane, Vijay Ashok Ahire, Rajesh Vyas, Nandu Baban Bhise, Girij Pal Singh
  • DESICCANT CONTAINER
    Publication number: 20130213828
    Abstract: The present application relates to a container for storing tablets and/or capsules. The container may include an upper portion and a bottom portion which defines an integrated chamber, rib profile and a separator means snap-locked in the rib profile. The separator means may include perforated disc means.
    Type: Application
    Filed: October 1, 2011
    Publication date: August 22, 2013
    Applicant: LUPIN LIMITED
    Inventors: Abhijit Chatterjee, Ramesh Rajendra Shetty
  • Antiemetic-oral contraceptive combination
    Patent number: 8507465
    Abstract: The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and/or estrogen and an antiemetic. The preferred oral contraceptive formulation comprises of levonorgestrel and an antiemetic.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: August 13, 2013
    Assignee: Lupin Limited
    Inventors: Sheetal Kulkarni, Srirupa Das, Harshal Anil Jahagirdar, Satish Dalal, Shirish Kulkarni
  • TASTE-MASKED POWDER FOR SUSPENSION COMPOSITIONS OF METHYLPREDNISOLONE
    Publication number: 20130203721
    Abstract: A dry taste masked powder composition comprising a steroid or its salts or derivatives and pharmaceutically acceptable excipients. The taste-masked powder may be used for suspension compositions suitable for use as a liquid suspension for children and elderly patients.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 8, 2013
    Applicant: LUPIN LIMITED
    Inventors: Pravin Meghrajji Bhutada, Ashishi Ashokrao Deshmukh, Prakash Bhagwat Gore, Umesh Ganesh Badhe, Sajeev Chandran, Shirishkumar Kulkarni
  • PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES
    Publication number: 20130174651
    Abstract: The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro -3 -furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof.
    Type: Application
    Filed: September 5, 2011
    Publication date: July 11, 2013
    Applicant: LUPIN LIMITED
    Inventors: Surinder Kumar Arora, Samir Shanteshwar Shabade, Gaurav Kumar, Purna Chandra Ray, Girij Pal Singh
  • CANNABINOID RECEPTOR MODULATORS
    Publication number: 20130178457
    Abstract: Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).
    Type: Application
    Filed: July 5, 2012
    Publication date: July 11, 2013
    Applicant: LUPIN LIMITED
    Inventors: Sanjeev Anant KULKARNI, Sachin MADAN, Nirmal Kumar JANA, Prashant Vitthalrao TALE, Narasimha Murthy CHEEMALA, Sachin Jaysing MAHANGARE, Prashant Popatrao VIDHATE, Chaitanya Prabhakar KULKARNI, Sapana Suresh PATEL, Amolsing Dattu PATIL, Seema Prabhakar ZADE, Rohan Mahadev SHINDE, Venkata P. PALLE, Rajender Kumar KAMBOJ
  • Polymomorph of desvenlafaxine benzoate
    Patent number: 8481596
    Abstract: The present invention relates to a novel crystalline form L of (±)-desvenlafaxine benzoate and process for the preparing of the same. Further, the present invention also relates to pharmaceutical composition of novel crystalline form L of desvenlafaxine benzoate and one or more pharmaceutically acceptable excipient.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: July 9, 2013
    Assignee: Lupin Limited
    Inventors: Gurvinder Pal Singh, Dabeer Rauf Karnalkar, Hemraj Mahadeorao Lande, Girij Pal Singh
  • Controlled Release Pharmaceutical Compositions of Milnacipran
    Publication number: 20130156854
    Abstract: A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts there—of is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents.
    Type: Application
    Filed: August 26, 2011
    Publication date: June 20, 2013
    Applicant: LUPIN LIMITED
    Inventors: Shirishkumar Kulkarni, Rajesh Kulkarni, Pandharinath Jadhav, Ashish Tiwari
  • ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BLONANSERIN
    Publication number: 20130143897
    Abstract: An oral controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) and optionally pharmaceutically acceptable excipients is provided. The present invention further relates to a controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) such that the composition releases not less than about 80% of Blonanserin within 20 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm for 20 hrs. The controlled release pharmaceutical composition of the invention releases 50% of Blonanserin between about 4 to 14 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm.
    Type: Application
    Filed: August 10, 2011
    Publication date: June 6, 2013
    Applicant: LUPIN LIMITED
    Inventors: Pravin Meghrajji Bhutada, Ashish Ashokrao Deshmukh, Sajeev Chandran, Shirishkumar Kulkarni
  • PHARMACEUTICAL COMPOSITIONS OF CEFDITOREN PIVOXIL
    Publication number: 20130143857
    Abstract: The present invention relates to a pharmaceutical composition comprising Cefditoren pivoxil, water soluble high molecular weight substance and one or more pharmaceutically acceptable excipient wherein weight ratio of high molecular weight substance to Cefditoren pivoxil is greater than 1:4 and a process for preparation thereof.
    Type: Application
    Filed: July 14, 2011
    Publication date: June 6, 2013
    Applicant: LUPIN LIMITED
    Inventors: Ashish Guha, Bharat Metkar, Makrand Avachat
  • CONTROLLED RELEASE FORMULATIONS OF DRONEDARONE
    Publication number: 20130142849
    Abstract: The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day.
    Type: Application
    Filed: August 13, 2011
    Publication date: June 6, 2013
    Applicant: LUPIN LIMITED
    Inventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirish Kulkarni